Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Agency

All agencies FDA (Food)FDA (Drugs)FDA (Devices)USDA FSIS CPSC NHTSA EPA

9276–9300 of 17987

CriticalFDA (Drugs)·D-1178-2018·2018-08-29
FDA Recalls Levothyroxine and Liothyronine Thyroid Tablets Due to Content Uniformity Failures
Westminster Pharmaceuticals is recalling specific lots of Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient.
Product
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1 grain (60 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-156-04.
Category
Drug
Distribution
Distributed nationwide
CriticalFDA (Drugs)·D-1182-2018·2018-08-29
FDA Recalls Levothyroxine and Liothyronine Thyroid Tablets Due to Content Uniformity Failures
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications, potentially resulting in incorrect drug strength.
Product
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 2 grain (120 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-158-04.
Category
Drug
Distribution
Distributed nationwide
CriticalFDA (Drugs)·D-1181-2018·2018-08-29
FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Product
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1/4 grain (15 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-159-04.
Category
Drug
Distribution
Distributed nationwide
CriticalFDA (Drugs)·D-1180-2018·2018-08-29
FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Product
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1/2 grain (30 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-155-04.
Category
Drug
Distribution
Distributed nationwide
CriticalFDA (Drugs)·D-1179-2018·2018-08-29
FDA Recalls Levothyroxine and Liothyronine Tablets Due to Content Uniformity Failures
Westminster Pharmaceuticals is recalling Levothyroxine and Liothyronine tablets because they failed content uniformity specifications due to an adulterated ingredient and poor manufacturing controls.
Product
Levothyroxine and Liothyronine (Thyroid Tablets, USP), 1 & 1/2 grain (90 mg), 100-count bottles, Rx Only, Manufactured for: Westminster Pharmaceuticals, LLC, 154 Downing Street, Unit 1 & 2, Olive Branch, MS 38654, NDC 69367-157-04.
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1109-2018·2018-08-29
A-S Medication Solutions Recalls Valsartan Tablets Due to Carcinogen Impurity
A-S Medication Solutions LLC is recalling 178 bottles of Valsartan Tablets, 80 MG, because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
Valsartan Tablets, 80 MG, 30-count bottle (NDC 54569-6582-0, 90-count bottle (NDC 54569-6582-1), Rx Only, MFG: Zhejiang Huahai Pharma, Linhai, Zhejiang 317024 China
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1111-2018·2018-08-29
A-S Medication Solutions Recalls Valsartan and Hydrochlorothiazide Tablets
A-S Medication Solutions LLC is recalling 531 bottles of Valsartan and Hydrochlorothiazide Tablets due to the detection of a carcinogen impurity in the active pharmaceutical ingredient.
Product
Valsartan and Hydrochlorothiazide Tablets, Valsartan 320 MG and Hydrochlorothiazide 25 MG, 90 tablets per bottle, Rx Only, MFG: Arrow Pharm (Malta) LTD, Birzebbugia, BBG 3000 Malta. NDC: 54569-6488-0
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1116-2018·2018-08-29
Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity
Hetero Labs is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1114-2018·2018-08-29
Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity
Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1107-2018·2018-08-29
Preferred Pharmaceuticals Recalls Valsartan Tablets Due to Carcinogen Impurity
Preferred Pharmaceuticals is recalling Valsartan Tablets USP 320 mg because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
Valsartan Tablets USP 320 mg, 90-count, plastic child resistant bottle, Rx Only, Preferred Pharmaceuticals, Inc., 1250 N. Lakeview Ave., Suite O, Anaheim, CA 92807, NDC 68788-6882-9
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1110-2018·2018-08-29
A-S Medication Solutions Recalls Valsartan and Hydrochlorothiazide Tablets
A-S Medication Solutions LLC is recalling Valsartan and Hydrochlorothiazide Tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
Valsartan and Hydrochlorothiazide Tablets, Valsartan 160 MG and Hydrochlorothiazide 12.5 MG, 90 tablets per bottle, Rx Only, MFG: Arrow Pharm (Malta) LTD, Birzebbugia, BBG 3000 Malta. NDC: 54569-6480-0
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1115-2018·2018-08-29
Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity
Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1108-2018·2018-08-29
A-S Medication Solutions Recalls Valsartan Tablets Due to Carcinogen Impurity
A-S Medication Solutions LLC is recalling Valsartan Tablets 160 MG because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
Valsartan Tablets, 160 MG, 30-count bottle (NDC 54569-6583-0), 90-count bottle (NDC 54569-6583-1), Rx Only, MFG: Zhejiang Huahai Pharma, Linhai, Zhejiang 317024 China
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1113-2018·2018-08-29
Hetero Labs Recalls Valsartan Tablets Due to Carcinogen Impurity
Hetero Labs Limited is recalling Valsartan tablets because a carcinogen impurity was detected in the active pharmaceutical ingredient.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
Distributed nationwide
ModerateFDA (Drugs)·D-1106-2018·2018-08-29
Jubilant Cadista Recalls Valsartan Tablets Due to Incorrect Excipient Grade
Jubilant Cadista Pharmaceuticals is recalling 7,048 bottles of Valsartan 320 mg tablets because an incorrect grade of excipient may have been used during manufacturing.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
0 states
ModerateFDA (Drugs)·D-1104-2018·2018-08-29
Jubilant Cadista Recalls Valsartan Tablets Due to Potential Excipient Error
Jubilant Cadista Pharmaceuticals is recalling Valsartan tablets because an incorrect grade of excipient may have been used during manufacturing.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
0 states
LowFDA (Drugs)·D-1103-2018·2018-08-29
Jubilant Cadista Recalls Valsartan Tablets Due to Incorrect Excipient Grade
Jubilant Cadista Pharmaceuticals is recalling specific lots of Valsartan 40 mg tablets because an incorrect grade of excipient may have been used during manufacturing.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
0 states
LowFDA (Drugs)·D-1105-2018·2018-08-29
Jubilant Cadista Recalls Valsartan Tablets Due to Potential Excipient Error
Jubilant Cadista Pharmaceuticals is recalling 18,947 bottles of Valsartan 160 mg tablets because an incorrect grade of excipient may have been used during manufacturing.
Product
VALSARTAN — VALSARTAN (VALSARTAN)
Category
Drug
Distribution
0 states
LowFDA (Drugs)·D-1112-2018·2018-08-29
Mylan Recalls Diltiazem HCl Extended-release Capsules Due to Impurities
Mylan Institutional, Inc. is recalling 408 cartons of Diltiazem HCl Extended-release Capsules, 120 mg, due to out-of-specification impurities.
Product
Diltiazem HCl Extended-release Capsules, USP 120 mg, 80 capsules, 8 blister cards of 10 capsules each per carton, Rx Only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV. NDC 51079-947-08
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-1091-2018·2018-08-22
Ranier's Compounding Laboratory Recalls PRASH Injection Due to Sterility Concerns
Ranier's Compounding Laboratory is recalling PRASH Injection vials because practices at the firm may call into question the sterility of the product.
Product
PRASH 12.2mcg/1.22m/19.29 (Prostaglandin/Phentolamine/Papaverine) Injection, 10 mL vial, Rx only, Ranier's Rx Laboratory, 1107 Lowry Avenue Suite A, Jeannette, PA 15644.
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1092-2018·2018-08-22
Ranier's Compounding Laboratory Recalls Prostaglandin Injection Due to Sterility Concerns
Ranier's Compounding Laboratory is recalling Pro/PA/PH/AT Injection in Pennsylvania due to a lack of assurance of sterility.
Product
PRO/PA/PH/AT 18mcg/1.8mg/ (Prostaglandin//Papaverine/Phentolamine/Atropine) Injection, 18mcg/1.8 mg/0.2 mg/0.02 mg/mL, 10 mL vial, Rx only, Ranier's Rx Laboratory, 1107 Lowry Avenue Suite A, Jeannette, PA 15644.
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1082-2018·2018-08-22
Ranier's Compounding Laboratory Recalls Avastin Prefilled Syringes Due to Sterility Concerns
Ranier's Compounding Laboratory is recalling 213 Avastin prefilled syringes because practices at the firm may call into question the sterility of the products.
Product
Avastin 1.25 mg/0.05 mL prefilled syringe, Rx only, Ranier's Rx Laboratory, 1107 Lowry Avenue Suite A, Jeannette, PA 15644.
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1090-2018·2018-08-22
Ranier's P/P/P Injection Recalled for Sterility Assurance Concerns
Ranier's Compounding Laboratory is recalling P/P/P Injection vials because practices at the firm may call into question the sterility of the products.
Product
P/P/P (Prostaglandin/Papaverine/Phentolamine) Injection, 0.02/30/2 mg/mL, 5 mL vial, Rx only, Ranier's Rx Laboratory, 1107 Lowry Avenue Suite A, Jeannette, PA 15644.
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1093-2018·2018-08-22
Ranier's Compounding Laboratory Recalls P/P/P Injection Due to Sterility Concerns
Ranier's Compounding Laboratory is recalling P/P/P Injection vials because practices at the firm may call into question the sterility of the product.
Product
P/P/P 0.02/40/2mg/mL(Prostaglandin//Papaverine/Phentolamine) Injection, 0.02/40/2 mg/mL, 1 mL vial, Rx only, Ranier's Rx Laboratory, 1107 Lowry Avenue Suite A, Jeannette, PA 15644.
Category
Drug
Distribution
1 state
SevereFDA (Drugs)·D-1088-2018·2018-08-22
Ranier's Medroxprogesterone Ophthalmic Solution Recalled for Sterility Concerns
Ranier's Compounding Laboratory is recalling Medroxprogesterone 1% Ophthalmic Solution due to a lack of assurance of sterility. The product was distributed in Pennsylvania.
Product
Medroxprogesterone 1% Ophthalmic Solution, 10 mL droptainer, Rx only, Ranier's Rx Laboratory, 1107 Lowry Avenue Suite A, Jeannette, PA 15644.
Category
Drug
Distribution
1 state

How to read this listing

Filters

9276–9300 of 17987